Squarepoint
BMY icon

Squarepoint’s Bristol-Myers Squibb BMY Stock Holding History

Squarepoint’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.33M Sell
109,800
-148,500
-57% -$8.53M 0.01% 1397
2026
Q1 		$15.7M Buy
258,300
+62,900
+32% +$3.67M 0.02% 824
2025
Q4 		$10.5M Sell
195,400
-78,100
-29% -$3.76M 0.01% 1054
2025
Q3 		$12.3M Sell
273,500
-82,400
-23% -$3.85M 0.01% 974
2025
Q2 		$16.5M Buy
355,900
+237,600
+201% +$11.7M 0.02% 860
2025
Q1 		$7.22M Sell
118,300
-219,800
-65% -$12.8M 0.01% 1210
2024
Q4 		$19.1M Buy
338,100
+94,800
+39% +$5.3M 0.02% 793
2024
Q3 		$12.6M Sell
243,300
-103,900
-30% -$4.87M 0.02% 832
2024
Q2 		$14.4M Sell
347,200
-804,200
-70% -$36M 0.02% 742
2024
Q1 		$62.4M Buy
1,151,400
+845,500
+276% +$43.1M 0.11% 193
2023
Q4 		$15.7M Sell
305,900
-139,400
-31% -$7.32M 0.03% 687
2023
Q3 		$25.8M Buy
445,300
+280,200
+170% +$17.2M 0.06% 350
2023
Q2 		$10.6M Buy
165,100
+6,300
+4% +$422K 0.03% 639
2023
Q1 		$11M Buy
158,800
+51,800
+48% +$3.65M 0.04% 500
2022
Q4 		$7.7M Buy
107,000
+19,400
+22% +$1.46M 0.03% 632
2022
Q3 		$6.23M Buy
87,600
+4,900
+6% +$355K 0.03% 630
2022
Q2 		$6.37M Buy
82,700
+5,100
+7% +$388K 0.04% 563
2022
Q1 		$5.67M Buy
77,600
+71,900
+1,261% +$4.83M 0.02% 675
2021
Q4 		$355K Buy
+5,700
New +$334K ﹤0.01% 2361
2021
Q3 		– Sell
-42,000
Closed -$2.81M – 2932
2021
Q2 		$2.81M Buy
+42,000
New +$2.74M 0.01% 996
2021
Q1 		– Sell
-22,200
Closed -$1.38M – 3133
2020
Q4 		$1.38M Buy
+22,200
New +$1.37M 0.01% 1143
2020
Q1 		– Sell
-3,600
Closed -$231K – 1901
2019
Q4 		$231K Sell
3,600
-1,900
-35% -$109K ﹤0.01% 2165
2019
Q3 		$279K Buy
+5,500
New +$258K ﹤0.01% 1938

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Squarepoint's BMY Position: Q2 2026 in Review

Squarepoint increased its Bristol-Myers Squibb (BMY) stake by 500% in Q2 2026, buying an estimated $15.5M and bringing the position to 324,626 shares worth $18.7M. The position accounts for 0.02% of the portfolio, ranked #723.

Squarepoint first reported a position in BMY in Q1 2015 and has held it in 40 quarters since. The position peaked at $184M in Q4 2023. 2,517 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Squarepoint held 324,626 shares of Bristol-Myers Squibb worth $18.7M as of Q2 2026.
  • Squarepoint bought 270,492 Bristol-Myers Squibb shares in Q2 2026, an estimated $15.5M.
  • Bristol-Myers Squibb made up 0.02% of Squarepoint's portfolio in Q2 2026, its #723 holding.
  • Squarepoint first reported a position in Bristol-Myers Squibb in Q1 2015 and has held it in 40 quarters since.
  • Squarepoint's Bristol-Myers Squibb position peaked at $184M in Q4 2023.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.